Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11.68 % -62.4%
Debt-to-equity -229 % +30.4%
Return On Equity 70.29 % -21.1%
Return On Assets -54.54 % -40.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36,329,842 shares +0.41%
Common Stock, Shares, Outstanding 3,622,842 shares -90%
Entity Public Float 30,300,000 USD +1.4%
Common Stock, Value, Issued 362,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 36,226,285 shares +0.13%
Weighted Average Number of Shares Outstanding, Diluted 36,226,285 shares +0.13%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12,306,000 USD -5.6%
Operating Income (Loss) -33,349,000 USD +19.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46,901,000 USD -13.4%
Earnings Per Share, Basic -1 USD/shares -14%
Earnings Per Share, Diluted -1 USD/shares +24.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14,756,000 USD -13.9%
Other Assets, Current 759,000 USD -65.8%
Assets, Current 16,930,000 USD -24.4%
Property, Plant and Equipment, Net 12,560,000 USD -7.8%
Operating Lease, Right-of-Use Asset 39,917,000 USD -5.5%
Intangible Assets, Net (Excluding Goodwill) 10,256,000 USD 0%
Goodwill 3,490,000 USD 0%
Other Assets, Noncurrent 973,000 USD +28.9%
Assets 89,516,000 USD -8.9%
Accounts Payable, Current 1,280,000 USD -29.5%
Liabilities, Current 139,950,000 USD +18.4%
Deferred Income Tax Liabilities, Net 3,077,000 USD 0%
Operating Lease, Liability, Noncurrent 26,837,000 USD -3.9%
Liabilities 185,104,000 USD +24.1%
Retained Earnings (Accumulated Deficit) -377,236,000 USD -14.2%
Stockholders' Equity Attributable to Parent -95,588,000 USD -87.5%
Liabilities and Equity 89,516,000 USD -8.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7,580,000 USD +28.4%
Net Cash Provided by (Used in) Financing Activities 9,986,000 USD -71.4%
Net Cash Provided by (Used in) Investing Activities -99,000 USD +60.4%
Common Stock, Shares Authorized 217,000,000 shares 0%
Common Stock, Shares, Issued 36,229,842 shares +0.13%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2,307,000 USD -90.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20,146,000 USD -10.9%
Deferred Tax Assets, Valuation Allowance 84,217,000 USD +12%
Deferred Tax Assets, Gross 97,112,000 USD +11.9%
Operating Lease, Liability 31,362,000 USD -4.7%
Depreciation 1,500,000 USD +15.4%
Payments to Acquire Property, Plant, and Equipment 99,000 USD -60.4%
Lessee, Operating Lease, Liability, to be Paid 61,002,000 USD -7.7%
Property, Plant and Equipment, Gross 26,819,000 USD +1.7%
Operating Lease, Liability, Current 4,525,000 USD -9.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5,452,000 USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 5,293,000 USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29,640,000 USD -10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5,616,000 USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 53,618,000 USD +15.1%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5,784,000 USD +3%
Operating Lease, Payments 1,671,000 USD -50.2%
Additional Paid in Capital 281,286,000 USD +0.82%
Depreciation, Depletion and Amortization 377,000 USD +18.9%
Share-based Payment Arrangement, Expense 2,332,000 USD -14.6%
Interest Expense 2,718,000 USD